

PTO/SB/088 (04-03)

Approved for use through 04/30/2003. OMB 0591-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/088,425
		Filing Date	03/15/2002
		First Named Inventor	Hiroaki SHIBASAKI et al.
		Art Unit	1628
		Examiner Name	J.C. Murphy
Sheet 1 of 1	Attorney Docket Number	1576.09	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DNW	3	BOOTH B L ET AL., "Synthesis of [1a, 2B, 3a-2-3-bis (benzyl/oxymethyl)pyridobutylimidazol-5-amine: important precursors to cylobut-A derivatives," J. Chem. Soc., Perkins Transactions, 1 ed., p. 669 - 675, (May 8, 1995).	
DNW	4	ALVES M J ET AL., "Synthesis of 5-Amino-4-(cyanoformimidohy)-1H-imidazole: a Reactive Intermediate for the Synthesis of 6-Carbamoyl-1,2-dihydropurines and 6-Carbamoyl-purines," J. Chem Soc., Perkins Trans. 1 ed., p. 1705-1712, (May 8, 1990).	✓
DNW	5	SHUMAN R F ET AL., "Chemistry of HCN. I. Formation and Reactions of N-(Aminomethylidene)diaminomaleonitrile, an HCN Pentamer and Precursor to Adenine," J. Org. Chem., Vol. 44 (No. 25), p. 4532 - 4536, (May 8, 1979).	✓
DNW	6	ALVES M J ET AL., "Synthesis of 4- and 5-Disubstituted 1-Benzylimidazoles, Important Precursors of Purine Analogs," Journal of Heterocyclic Chemistry, Vol. 31, p. 343 - 350, (1993-03).	✓

Examiner Signature	<i>Anna Wright</i>	Date Considered	4-6-04
--------------------	--------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 802. Draw line through citation if not in conformance and not considered. Include copy of this form with oral communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.86. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-0199 (1-800-786-0199) and select option 2.